SMMT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Not a good buy right now. Despite a strong FDA BLA acceptance headline, SMMT’s price action and momentum are decisively bearish (below key pivot and under bearish moving averages), and Intellectia has no buy signals today. For an impatient buyer unwilling to wait for a cleaner entry, the current setup is unfavorable—better to stay on the sidelines until the stock stabilizes back above near-term resistance levels.
Trend/momentum is bearish. The moving averages are stacked bearishly (SMA_200 > SMA_20 > SMA_5), indicating a sustained downtrend. MACD histogram is negative (-0.249) and expanding lower, confirming weakening momentum. RSI(6) at ~22 is deeply oversold (even if labeled “neutral” in the feed), which can spark short bounces, but oversold alone is not a reliable buy signal while MACD and MAs remain bearish. Price (14.64) is below S1 (14.855) and well below the pivot (16.207), implying broken support and overhead supply; next key support is S2 (14.019). A reclaim of 14.86 first, then 16.21, would be the earliest technical evidence of stabilization.
Intellectia Proprietary Trading Signals
Barclays upgrade to Equal Weight with PT raised to $18 highlights perceived upside tied to 2026 lung cancer updates.
Current tape is weak: sharp down day (-4.03%) and pre-market softness, with broken near-term support (below S1). Wolfe Research initiation flagged risk that Harmoni-2 may not show an overall survival benefit—an important clinical/valuation risk. Very high implied volatility suggests the market is braced for large moves; downside can remain painful if sentiment flips. No supportive insider or hedge fund accumulation trends noted in the provided data.
Latest reported quarter: 2025/Q3. The company remains effectively pre-revenue (revenue shown as 0). Losses are large: net income -$231.793M and EPS -0.31, indicating continued heavy burn and no near-term fundamental earnings support; the YoY deltas shown indicate the loss profile remains significant rather than improving in a way that would underpin a near-term technical reversal.
Recent Street tone is mixed. Barclays (2025-12-17) upgraded to Equal Weight from Underweight and raised the price target to $18 (from $16), citing meaningful 2026 lung cancer updates and multiple tumor-type opportunities (pro). Wolfe Research (2025-11-17) initiated at Peer Perform with no price target and raised concern that Harmoni-2 may not demonstrate an overall survival benefit (con). Overall: Wall Street sees upside tied to clinical/regulatory progress, but maintains material efficacy-risk skepticism, which aligns with the current choppy/volatile trading.
